semaglutide connective tissue targets muscle mitochondria to regulate glutamine metabolism and treat osteoarthritis Cardio-kidney-metabolic protective effects of semaglutide
Description
Phase 3 trials ongoing, NDA expected Q4 2026, approval late 2027-2028
Semaglutide is a new weight loss peptide that has been taking the world by storm, but does it work
Efficacy and safety of semaglutide 2.4 mg in the Japanese subgroup of the ESSENCE study
Indias pharma industry is strong
